Influenza B Virus Pool (Control Antigen) 2113

$75.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Cost-effective due to standardized reagents
Lyophilized antigens, control antigens as well as positive and negative control sera simplify storage
Suitable screening test to identify acute infections
Compensation of seroprevalences allow high specificity

SKU: 2113 Category: Infectious disease proteins Tags: antigen, Influenza Virus, protein

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Influenza B immunoglobulins
species reactivity	Influenza B
applications	CFT (Complement fixation test)
assay type	qualitative
available size	1 mL

Influenza B Virus Pool (Control Antigen) 2113

kit
Research area Infectious Disease
Storage Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Associated products Coxiella burnetii Phase 2 IgG Control Serum (BC1312G) Coxiella burnetii Phase 2 IgM Control Serum (BC1312M) Coxiella burnetii IgA Phase I ELISA Kit (ESR1311A) Coxiella burnetii IgG Phase I ELISA Kit (ESR1311G) Coxiella burnetii IgG Phase II ELISA Kit (ESR1312G) Coxiella burnetii IgM Phase II ELISA Kit (ESR1312M)

target relevance
Protein names Influenza Virus A

Data

FAQ & Publications

Frequently Asked Questions

What is the primary application of the Influenza B Virus Pool (Control Antigen) 2113?

The Influenza B Virus Pool (Control Antigen) 2113 is primarily used in the Complement Fixation Test (CFT) as a qualitative assay to identify acute infections by detecting Influenza B immunoglobulins.

How should the Influenza B Virus Pool (Control Antigen) 2113 be stored to maintain its stability?

This control antigen should be stored at -65°C and freeze/thaw cycles should be avoided. Additionally, it is recommended to sonicate the antigen before use to ensure proper dispersion.

Is the Influenza B Virus Pool (Control Antigen) 2113 suitable for detecting immune responses specific to Influenza B virus?

Yes, the product is reactive specifically to Influenza B species and targets Influenza B immunoglobulins, making it suitable for research involving Influenza B virus immune responses.

What are the advantages of using the Influenza B Virus Pool (Control Antigen) 2113 in research?

This antigen is cost-effective due to standardized reagents and simplifies storage through lyophilized format. It also allows for compensation of seroprevalences to achieve high specificity in screening tests for acute infections.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.